• Clinical Trials - Hepatitis C (HCV)

    Study Objective Contact
    A Multi-Center, Randomized, Prospective Open- Label Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin (HCIG) in Orthotopic Liver Transplant Recipients [LCID Study Number: 2014-023] This purpose of this study is to test the safety of different doses of the investigational therapy Hepatitis C Immune Globulin (HCIG) when given to patients with Hepatitis-C (HCV) who undergo liver transplantation. Principal Investigator(s):
    Fredric D. Gordon, MD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Agnes P. Trabucco,
    Erick Marangos.